Search

Your search keyword '"Lagier, Robert J."' showing total 19 results
Start Over Author "Lagier, Robert J."
19 results on '"Lagier, Robert J."'

2. Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer's disease assessment.

Author

Weber, Darren M., Taylor, Steven W., Lagier, Robert J., Kim, Jueun C., Goldman, Scott M., Clarke, Nigel J., Vaillancourt, David E., Duara, Ranjan, McFarland, Karen N., Wei-en Wang, Golde, Todd E., and Racke, Michael K.

Subjects
ALZHEIMER'S disease, LIQUID chromatography-mass spectrometry, POSITRON emission tomography, CEREBRAL amyloid angiopathy
Abstract

Introduction: Plasma Aβ42/40 ratio can help predict amyloid PET status, but its clinical utility in Alzheimer's disease (AD) assessment is unclear. Methods: Aβ42/40 ratio was measured by LC-MS/MS for 250 specimens with associated amyloid PET imaging, diagnosis, and demographic data, and for 6,192 consecutive clinical specimens submitted for Aβ42/40 testing. Results: High diagnostic sensitivity and negative predictive value (NPV) for Aβ- PET positivity were observed, consistent with the clinical performance of other plasma LC-MS/MS assays, but with greater separation between Aβ42/40 values for individuals with positive vs. negative Aβ-PET results. Assuming a moderate prevalence of Aβ-PET positivity, a cutpoint was identified with 99% NPV, which could help predict that AD is likely not the cause of patients' cognitive impairment and help reduce PET evaluation by about 40%. Conclusion: High-throughput plasma Aβ42/40 LC-MS/MS assays can help identify patients with low likelihood of AD pathology, which can reduce PET evaluations, allowing for cost savings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium

Author

Birse, Charles E., primary, Lagier, Robert J., additional, FitzHugh, William, additional, Pass, Harvey I., additional, Rom, William N., additional, Edell, Eric S., additional, Bungum, Aaron O., additional, Maldonado, Fabien, additional, Jett, James R., additional, Mesri, Mehdi, additional, Sult, Erin, additional, Joseloff, Elizabeth, additional, Li, Aiqun, additional, Heidbrink, Jenny, additional, Dhariwal, Gulshan, additional, Danis, Chad, additional, Tomic, Jennifer L., additional, Bruce, Robert J., additional, Moore, Paul A., additional, He, Tao, additional, Lewis, Marcia E., additional, and Ruben, Steve M., additional

Published
2015
Full Text
View/download PDF

16. Neither Replication nor Simulation Supports a Role for the Axon Guidance Pathway in the Genetics of Parkinson's Disease

Author

Li, Yonghong, primary, Rowland, Charles, additional, Xiromerisiou, Georgia, additional, Lagier, Robert J., additional, Schrodi, Steven J., additional, Dradiotis, Efthimios, additional, Ross, David, additional, Bui, Nam, additional, Catanese, Joseph, additional, Aggelakis, Konstantinos, additional, Grupe, Andrew, additional, and Hadjigeorgiou, Georgios, additional

Published
2008
Full Text
View/download PDF

17. Neither Replication nor Simulation Supports a Role for the Axon Guidance Pathway in the Genetics of Parkinson's Disease.

Author

Yonghong Li, Rowland, Charles, Xiromerisiou, Georgia, Lagier, Robert J., Schrodi, Steven J., Dradiotis, Efthimios, Ross, David, Bui, Nam, Catanese, Joseph, Aggelakis, Konstantinos, Grupe, Andrew, and Hadjigeorgiou, Georgios

Subjects
PARKINSON'S disease & genetics, NUCLEOTIDES, GENETIC polymorphisms, GENETIC markers, AXONS, HEALTH risk assessment, GENOMICS, HUMAN genome, GENETIC models
Abstract

Susceptibility to sporadic Parkinson's disease (PD) is thought to be influenced by both genetic and environmental factors and their interaction with each other. Statistical models including multiple variants in axon guidance pathway genes have recently been purported to be capable of predicting PD risk, survival free of the disease and age at disease onset; however the specific models have not undergone independent validation. Here we tested the best proposed risk panel of 23 single nucleotide polymorphisms (SNPs) in two PD sample sets, with a total of 525 cases and 518 controls. By single marker analysis, only one marker was significantly associated with PD risk in one of our sample sets (rs6692804: P = 0.03). Multimarker analysis using the reported model found a mild association in one sample set (two sided P = 0.049, odds ratio for each score change = 1.07) but no significance in the other (two sided P = 0.98, odds ratio = 1), a stark contrast to the reported strong association with PD risk (P = 4.64610-38, odds ratio as high as 90.8). Following a procedure similar to that used to build the reported model, simulated multi-marker models containing SNPs from randomly chosen genes in a genome wide PD dataset produced P-values that were highly significant and indistinguishable from similar models where disease status was permuted (3.13610-23 to 4.90610-64), demonstrating the potential for overfitting in the model building process. Together, these results challenge the robustness of the reported panel of genetic markers to predict PD risk in particular and a role of the axon guidance pathway in PD genetics in general. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

18. Abstract 11923: Annual Screening and Digital Behavioral Counseling in a Workplace Setting Reduce 10-year Cardiovascular Risk

Author

Iakoubova, Olga, Lagier, Robert J, Fragala, Maren S, McNamara, Kelsey, Castro Sweet, Cynthia M, and Birse, Charles E

Abstract

Background:Behavioral counseling has been shown to improve modifiable cardiovascular risk factors. We asked whether the 10-year risk for ASCVD events could be reduced within the first year of a digital (on-line) counseling program.Methods:Individuals were included in the study if they (i) participated in an annual employer-sponsored wellness program with year-end biometric screening for 3 years (2016, 2017, and 2018), (ii) had metabolic syndrome at the end of 2017, and (iii) completed at least 9 lessons in a digital behavioral counseling program initiated at the beginning of 2018. Paired t-Tests and McNemar tests were used to assess changes in ASCVD risk before and after intervention.Results:The baseline characteristics of the 144 participants are shown in the table. Participants engaged in the counseling program for a mean of 8.9 months (SD, 1.3) and completed a mean of 24 lessons (SD, 12). In the year before participation in counseling (2016-2017), mean 10-year ASCVD risk increased from 3.5% to 4.4%, P=0.0002 for difference in the annual ASCVD risk change before and after the program. In the year after participation in the counseling program (2017-2018), mean 10-year ASCVD risk decreased from 4.4% to 3.6%, and the fraction of participants with 10-year ASCVD risk ?5% decreased from 30% to 22%: P=0.04. Metabolic syndrome was substantially reduced (p<0.0001), and CVD risk factors were shifted in a favorable direction (Table).Conclusions:In participants with metabolic syndrome digital behavioral counseling reduced 10-year ASCVD risk after the first year on the program.

Published
2019
Full Text
View/download PDF

19. Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer's disease assessment.

Author

Weber DM, Taylor SW, Lagier RJ, Kim JC, Goldman SM, Clarke NJ, Vaillancourt DE, Duara R, McFarland KN, Wang WE, Golde TE, and Racke MK

Abstract

Introduction: Plasma Aβ42/40 ratio can be used to help predict amyloid PET status, but its clinical utility in Alzheimer's disease (AD) assessment is unclear., Methods: Aβ42/40 ratio was measured by LC-MS/MS in 250 specimens with associated amyloid PET imaging, diagnosis, and demographic data, and 6,192 consecutive clinical specimens submitted for Aβ42/40 testing., Results: High diagnostic sensitivity and negative predictive value (NPV) for Aβ-PET positivity were observed, consistent with the clinical performance of other plasma LC-MS/MS assays, but with greater separation between Aβ42/40 values for individuals with positive vs negative Aβ-PET results. Assuming a moderate prevalence of Aβ-PET positivity, a cutpoint was identified with 99% NPV, which could help predict that AD is likely not the cause of patients' cognitive impairment and help reduce PET evaluation by about 40%., Discussion: Using high-throughput plasma Aβ42/40 LC-MS/MS assays can help reduce PET evaluations in patients with low likelihood of AD pathology, allowing for cost savings., Competing Interests: CONFLICT OF INTEREST STATEMENT Darren M. Weber, Steven W. Taylor, Robert J. Lagier, Jueun C. Kim, Scott M. Goldman, Nigel J. Clarke, and Michael K. Racke are employees of Quest Diagnostics. All other authors have nothing to disclose.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results